Jeffrey Berkowitz

Senior Strategic Advisor @ Click Therapeutics arrow icon

About Jeffrey Berkowitz

Jeffrey Berkowitz is the CEO of Real Endpoints and a Senior Strategic Advisor with extensive experience in the pharmaceutical and healthcare industries.

Known information

Jeffrey Berkowitz is the CEO of Real Endpoints and serves as a Senior Strategic Advisor. He is a board member of several pharmaceutical companies, including Lundbeck A/S. Berkowitz has a rich professional background, having held the position of Executive Vice President at United Health Group/Optum and served as President of Pharma, Specialty, and Global Market Access at Walgreens Boots Alliance. His career also includes senior roles at Merck and Schering-Plough. Recognized three times by PharmaVoice magazine as one of the 100 Most Inspiring Leaders in the Life Sciences in 2009, 2010, and 2012, Berkowitz has made significant contributions to the industry. He earned a JD from Brooklyn Law School and holds a BS in Political Science from Union College.

About Click Therapeutics

Click Therapeutics develops and commercializes software as prescription medical treatments, focusing on cognitive and neurobehavioral mechanisms to address unmet medical needs. Headquartered in New York, the company collaborates with major healthcare firms and has received significant funding and recognition for its innovative digital therapeutics.

report flag Report inaccurate information

People similar to Jeffrey Berkowitz

Austin C. Speier

Chief Strategy Officer @ Click Therapeutics

Austin C. Speier is the Chief Strategy Officer with a background in emerging technologies and neurobiology research.

Muzammil Mansuri

Senior Strategic Advisor @ Click Therapeutics

Muzammil Mansuri is a Senior Strategic Advisor and Venture Partner at F-Prime Capital, with extensive experience in executive roles at Sanofi, Gilead Sciences, and CGI Pharmaceuticals.

Austin Speier

Chief Strategy Officer @ Click Therapeutics

Austin Speier is the Chief Strategy Officer with a background in emerging technologies and neurodegeneration research.

Unlock exclusive insights

Sign up to reveal more information.

loader Sign up for free